Based on the Cellsource Co Ltd stock forecast from 0 analysts, the average analyst target price for Cellsource Co Ltd is not available over the next 12 months. Cellsource Co Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cellsource Co Ltd is Slightly Bullish , which is based on 9 positive signals and 6 negative signals. At the last closing, Cellsource Co Ltd’s stock price was JPY 995.00. Cellsource Co Ltd’s stock price has changed by -2.26% over the past week, -12.80% over the past month and -38.28% over the last year.
No recent analyst target price found for Cellsource Co Ltd
No recent average analyst rating found for Cellsource Co Ltd
Company Overview Cellsource Co Ltd
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients' adipose tissues, and to prepare platelet-rich plasma from patients' blood; and offers support services for medical facilities providing regenerative medicine therapy, as well as manufacturing processed cells. It is also involved in the development and sale of Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Tokyo, Japan. Read Less
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients' adipose tissues, and to prepare platelet-rich plasma from patients' blood; and offers support servi...Read More
Frequently Asked Questions About Cellsource Co Ltd (4880:TSE) Stock
Stock Target Advisor's fundamental analysis for Cellsource Co Ltd's stock is Slightly Bullish .
4880:TSE stock's dividend yield is 0.86%.
Our analysis grades 4880:TSE stock's dividend yield at F. This means that 4880:TSE stock's dividend yield is above 17% of the stocks in the Biotechnology sector in the TSE exchange.
Based on this 4880:TSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 4880:TSE's stock to indicate what its average analyst target is.
4880:TSE stock's Price/Earning ratio is 27.35.
Our analysis grades 4880:TSE stock's Price / Earning ratio at D. This means that 4880:TSE stock's Price/Earning ratio is above 35% of the stocks in the Biotechnology sector in the TSE exchange.
Based on this 4880:TSE may be fairly valued for its sector
The last closing price of 4880:TSE's stock was JPY 995.00.
The most recent market capitalization for 4880:TSE is JPY 22.60B.
Unfortunately we do not have enough analyst data on 4880:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cellsource Co Ltd's stock.
As per our most recent records Cellsource Co Ltd has 151 Employees.
Cellsource Co Ltd's registered address is SHIBUYA CAST., Tokyo, Japan, 150-0002.
You can get more information about it from Cellsource Co Ltd's website at https://www.cellsource.co.jp.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Cellsource Co Ltd (4880:TSE) Stock
Stock Target Advisor's fundamental analysis for Cellsource Co Ltd's stock is Slightly Bullish .
4880:TSE stock's dividend yield is 0.86%.
Our analysis grades 4880:TSE stock's dividend yield at F. This means that 4880:TSE stock's dividend yield is above 17% of the stocks in the Biotechnology sector in the TSE exchange.
Based on this 4880:TSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 4880:TSE's stock to indicate what its average analyst target is.
4880:TSE stock's Price/Earning ratio is 27.35.
Our analysis grades 4880:TSE stock's Price / Earning ratio at D. This means that 4880:TSE stock's Price/Earning ratio is above 35% of the stocks in the Biotechnology sector in the TSE exchange.
Based on this 4880:TSE may be fairly valued for its sector
The last closing price of 4880:TSE's stock was JPY 995.00.
The most recent market capitalization for 4880:TSE is JPY 22.60B.
Unfortunately we do not have enough analyst data on 4880:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cellsource Co Ltd's stock.
As per our most recent records Cellsource Co Ltd has 151 Employees.
Cellsource Co Ltd's registered address is SHIBUYA CAST., Tokyo, Japan, 150-0002.
You can get more information about it from Cellsource Co Ltd's website at https://www.cellsource.co.jp.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4880:TSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
